ADMA Biologics
ADMA
19 hedge funds and large institutions have $26M invested in ADMA Biologics in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding
Funds holding: 19 → 19 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
19.98% less ownership
Funds ownership: 69.13% → 49.15% (-20%)
49% less capital inflows, than outflows
Capital inflows: $2.07M | Capital outflows: $4.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IHM
Iguana Healthcare Management
New York
|
+$1.38M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$538K |
| 3 |
Millennium Management
New York
|
+$63.5K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$35.1K |
| 5 |
Renaissance Technologies
New York
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$2.52M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.34M |
| 3 |
Weiss Multi-Strategy Advisers
New York
|
-$74K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$49.3K |
| 5 |
SIM
Spark Investment Management
New York
|
-$39K |
ADMA Hedge Fund Activity: Q3 2017 in Review
19 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2017, worth a combined $26M — down 22% from $33.2M a quarter earlier.
Fund positioning in ADMA was balanced in Q3 2017: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Iguana Healthcare Management, adding an estimated $1.38M. The largest seller was Broadfin Capital, exiting entirely with an estimated $2.52M sold.
- 19 institutional investors held ADMA Biologics (ADMA) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $26M of ADMA Biologics stock for Q3 2017, down 22% quarter-over-quarter.
- 4 funds opened new ADMA Biologics positions in Q3 2017 and 4 closed out, a net change of 0 holders.
- The largest ADMA Biologics buyer in Q3 2017 was Iguana Healthcare Management, an estimated $1.38M added.
- The largest ADMA Biologics seller in Q3 2017 was Broadfin Capital, an estimated $2.52M sold.
Based on aggregated 13F filings for Q3 2017.